Relation between myocardial infarct location and stroke  by Bodenheimer, Monty M. et al.
ester and New York, New York 
f stroke is increased after myocardial infarction 
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a tant cause of stroke i 
reviews (5-8) recommend obtaining an 
in patients with an anterior myoca~djal 
viding anticoagulant therapy if thrombus is 
d, a~tbo~~b this procedure is not accepted universally 
(9). Yet, prospective studies have reported varying degrees 
of success with the use of anticoagulants to prevent tbrom- 
bus (W-14) or reduce the likelihood of stroke (12-18). 
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~othes~zed that if tI 
nterior infarction is 
with anterior infarction sbou 
increased incidence of stroke. 
trospective review of the 
in the Multicenter 
from February 17, 1983 to June 30, 1986. The rec~~tment 
procedure and inclusion and exclusion criteria have been 
previously reported (19). In brief, men or women 25 to 75 
years old who were admitted to the hospital and subse- 
quently documented to have had an acute myocardial infarc- 
tion were eligible. Patients were excluded if there was 
evidence of ongoing cardiogenic shock, pulmonary h 
e at~iovent~c~~ar block or other c 
ce survival. randomization took 
during hospital days 3 to I5 (median day 8) from the ti 
onset of the myocardial infarction. 
All patients were followed up for 12 to 52 ths (aver- 
age 25 months). Patients were seen by the investigator or 
clinical coordinator, or both, at periodic intervals throughout 
the trial. The MDPIT follow-up schedule consisted of five 
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1. Clinical Characteristics by Myocardial Infarct Site 
Covariate (no. of patients with anterior, 
nonanterior infarction) 
Age 260 yr (724, 1,740) 
Previous Ml (723. 1,739) 
NYIIA class II-IV (724. 1,740) 
History of hypertension (723, 1,739) 
Insulindependent diabetes (724, 1,740) 
Cigarette smoking (72 I, 1,727) 
Cardiachndings 
Systolic BP cl00 mm IIg (722, 1,734) 
Bibasiiar pulmonary rales (721,1,733) 
Cteatine kinase ~619 IJ (724, 1,739) 
brillation (724, 1,740) 
sis (at index MI) (724, 1,746) 
Site uf MI (%I 
Anterior Nonanterior v:ue 
50 51 0.795 
25 20 0.002 
19 18 a.553 
38 38 0.886 
9 8 0.243 
46 50 0.055 
2 5 0. 
4a 36 e 0. 
79 62 < 0. 
9 8 0. 
56 17 < 0. 
I2 7 < 0. 
Aspirin 22 24 0.145 
adrenergic blocking agents 49 56 0. 
abs 23 IO ==z 0. 
ridamole 8 7 0. 
Other antipkitelet agents 9 6 0.003 
Reinfatction (before CVA) (724. !,74ft! 0.28 0.34 0.785 
Warfaiin (at discharge) (724, 1,740) 19 4 
StroktiIA (724, 1.740)” 3 4 0.381 
‘Total t!Jmber of cerebrovascular events during follow-up (see text). BP = blood pressure; CVA = cerebrovas- 
cular accident; EF = eiection fraction: MI = myocardia! infarction; NYHA class = New York Heart Associatiun 
functional class; TIA i transient ischemic attack. 
visits in the first year (an initial visit at I month followed by 
a visit every 3 months), then a visit every 4 months until 
study closure. Bata retrieval t the clinic visit consisted ofan 
interval medical and cardiac history, review of concurrent 
medications and physical examinations. 
During these visits any adverse xperiences or interven- 
ing medical conditions, orboth, were noted and described on 
the clinical record forms. Stroke was not coded separately 
but included as either an adverse vent or an interval 
medical event. As a result, 1,731 medical follow-up repcsrts 
had to be reviewed. This review was performed by two of us 
(D.S. and B.S.) without knowledge ofthe site of the index 
myocardial infarction. 
A stroke was defined as an acute focal cere- 
bra) disorder’that resulted in localizing findings character- 
ized by either the patient’s physician or the clinical investi- 
tot as a cerebrovascular accident. If the duration of 
symptoms was ~24 h, the episode was defined as a transient 
ischemic attack (20). Nonlocalizing symptoms, uch as diz- 
ziness, giddiness or wooziness, or involuntary movements, 
such as limb shaking, were not classified as transient isch- 
emit attacks (20). Because this study was not prospectively 
designed, confirmation with computed tomography, anceph- 
alography and other procedures was not always available 
and was generally not recorded in the patient data. 
The diagnosis of acute myocardial nfarction required serum 
enzyme confirmation: a  MB isoenzyme fraction >4% of total 
Creatine kmase (CK) or a qualitatively positive MB band; an 
elevatiott of total Iactic deh 
reversal ofthe LD or an elevation of22 times 
normal of CK, se xaloa?etic transaminase or 
LDH in the coronary care unit with a clinically consistent 
pattern. Acute anterior wail myocardial nfarction was defined 
as Q waves appearing in leads V, to Vd; absence ofnew Q 
waves in these leads identified patients with nonanterior myo- 
catdial infarction (19). The latter group included patients with 
inferior or posterior Q wave infarction (61%) and those with 
non-Q wave infarction (39%), defined as elevated serum en- 
zY t with infarction without Q waves (19). 
Univariate analysis was performed to
determine the relation between baseline clinical variables 
and infarct site (Table I). A model was then constructed 
using Cox regression analysis with the occurrence ofstroke 
or transient ischemic attack as the dependent variable (21). 
All covariates with a p value I 0.10 were forced into the 
model. The use of warfarin was added to the model to 
determine its contribution, and it was maintained in the 
model regardless of its p value. The final model was con- 
structed by adding infarct site to the model (21). Results are 
expressed as hazard ratio with 95% confidence limits. A 
Rower analysis was performed todetermine the possibility of
a beta error (22). The effect of infarct site on time to end 
point was examined with the method of Kaplan and Meier. 
The log-rank statistic was used to compare Kaplan-Meier 
curves. Summary odds ratios were determined with the 
technique ofMantel and Haenszel(22). 
viva! curves for likeli 
fined RS stroke or 
attack, in patients wi!la a~it~ri~r or ~Q~~~t~rior m 
I) at the time of enro~lmc~t. 
acebo group and 44 ( 
patients with an event. 
level and lower 
of admission with the index myo- 
cardial infarction as we to be treated with 
infarction had a stroke or transient is 
pared with 68 (3.9%) of 1,742 patients with a nonanterior 
myocardial infarction (relative risk 0.82; 95% confidence 
interval [CI] 0.55 to 1.30). Power analysis revealed that his 
study had an 86% chance of detecting a relative risk of stroke 
of 1.5 in patients with anterior versus nonanterior infarction. 
When the patients with nonanterior infarction were classified 
into those with inferior or posterolateral Q waves a 
with nap-Q wave infarction, the likelih 
3.5% and 4.%, respectively. Figure 1 
Meier life table event rate for patients with anterior and 
nona r myocardial infarction. As is evident, no signifi- 
cant ence exists (p = 0.42 by log-rank test). When 
analyzed by infarct site and treatment with placebo r 
diltiazem, the findings were essentially the same (p - 0.35). 
Multivariate analysis (Table 2). Stepwise multivariate 
Cox analysis was used to determine variables that were 
Covariates 
Systolic BP* 





(1.007 to 1.021) 
0.930 
(0.397 to 2.179) 
0.F 





The hazard ratio for sys!olic blood pressure (BP) is per unit increase in 
, when compared with a patient with a systoli 
g, a patient with a systolic blood pressure of 150 
would have a hazard ratio of 1.014” (=1.97). CCU = coronary care unit; 
C1 = confidence interval. 
and transient isc 
s with anterior ~~~a~cti 
limiting the screening process to those with anterior infarc- 
tion (5-S). 
A~t~coa~w~~t~~~ an us ~~rrnat~Q~ (Ta 
Echocardiographic studies of the relation between anterior 
myocardial infarction, thrombus and stroke differ in meth- 
study oatients, timing of echocardiog~aphy~ ther- 
e including thrombolytic agents) and follow-up. 
e limitations inmind, pooling these studies hows 
that he likelihood of thrombus and embolization in patients 
with anterior infarction ishigh whether or not anticoagulants 
are used (Table 3). In four studies, patients were randomized 
to receive ither anticoagulants or placebo, although t rom- 
bolytic agents were sometimes u ed (1 l-14). Two studies 
(11,12) showed benefit, whereas two (13,l 
effect on left ventricular thrombus formation. 
studies (I 1-14) were combined, no coagulation was 
associated with an increased risk of th bus of 1.86 (95% 
CI 1.22 to 2.82). 
Thrombolytic agents have been reported to reduce throm- 
bus formation (27,31) or to have no effect (14,18,29,32). 
However, because anticoagulants are often used concur- 
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Norarandomized PooZ Studies 
Ref. IO, 15-18,23-32 653 169 (26%) 31* (4.7%) 497 203 (41%) 24t (4.8%) 
Randomized Trials of Anticoanulation and Left Ventricular Thrombus 
Vecchio et al. (14) 86 26 I 94 25 0 
SCAT) trial (12) 93 34 2 107 19 0 
Gueret et al. (13) 25 13 1 21 8 I 
hhnnesilcrn et al. (II) 21 7 2 21 0 1 
Totals 225 80 (36%) 6 (2.6%) 243 52 (21%) 2 (0.8%) 
‘21 strokes and IO nonccreblal emboli. K?O strokes and 4 noncerebral emboli. SCumulativc odds ratio of thrombus it patients without aflt~coag~~~tjo~ vm.us 
patients with antic ulation is 1.86 (95% confidence interval 1.22 to 2.82) with a chi-square of 8.36 with I degree of freedom. 
rently, any benefit may not reflect the effect of throm~o~ytic 
ents (14). 
The ability of anticoagulation to prevent stroke is also 
difficult to assess because of inadequate controls and a 
relative paucity of embolic events (Table 3). In the present 
study, warfarin was used in only 1% of patients with 
anterior infarction, raising the possibility of a type 2 error to 
he lack of contribution of warfarin to the model. 
of as Won on stroke in mtion pa- 
tlents, The role of anticoagulation in patients after acute 
myocardial infarction has been the subject of numerous 
studies. Aithouqh stroke has generally not been a primary 
prospectively aefined end point, we used previously pub- 
lished analyses (33-35) and a search of MEDLINE to find 
those randomized studies in which the incidence of stroke 
could be determined (Table 4) (36-44). As assessed with use 
of acumulative odds ratio and the mantel-~aenszel test (22). 
the risk of stroke was 2.05 (95% CI I.5 to 2.8) in patients 
randomized to placebo versus anticoagulation. Left unre- 
solved is the role of aspirin relative to coMmadi~ in this 
setting (45). 
(Table 1). 
Dexter et al. (4) found a higher than expected rate of 
stroke. particularly in the 1st 2 months after myocardial in- 
farction. Our study also shows a relatively higher rate within 
the 1st 2 months, with I8 of 91 strokes occurring during this 
period. However, the rates were similar for patients with 
anterior and nonanterior myocardial infarction (Fig. I). 
Table 4. Analysis of Randomized Studies of Anticoagulation After Myocardial Infarction: 
Incidence of Stroke 
Control Group Anticoagulation Group 
-- 
No. With No. With 
Study Total No. Stroke Total No. Stroke 
MRC (36) 188 I 195 3 
Wasserman et al. (37) 70 I 77 0 
Lovell et al. (38) 240 13 172 2 
Ritlsnd et al. (39) 101 2 97 0 
MRC (40) 715 I8 712 8 
Drapkin and Merskey (II) 391 9 145 13 
VA Coop (42) 499 16 500 4 
Sixty Plus Reinfarction (43) 439 21 439 I3 
Smith et al. (44) 607 44 607 20 
Total* 3,250 125 3,544 63 
*Summary odds ratio of stroke in patients in control groups compared with patients treated with anticoagulation 
is 2.05 (95% confidence interval I .50 to 2.80) with a chi-square of 20.6 with 1 degree of freedom. MRC = Medical 
Research Council: VA Coop = Veterans AtEM cooperative study. 
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prevent more than half of the cere~r~vasc~la~ events een inn 
our patients. Clearly, further studies are needed to deter- 
mine the mechanis of these events. U 
diagnostic riteria exist 
strokes from those with ot 
vascular atherosclerosis ( 
review of the ~~~lis~ed 
agulation even though o
therapy. The exact place of this strategy inrelation to other 
interventions remains to be determined with randomized 
trials (45). 
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